In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product ... down 6.8% from previous close. The stock market overreacts to news, and ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Once a trailblazer in ancestry DNA testing, 23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in demand and a 2023 data breach that exposed sensitive ...

To counter the decline in Eylea sales, Regeneron developed a higher dose ... Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

The trials revealed that only one of the two studies met the primary endpoint, casting doubt on the likelihood of approval. This news led to a significant 19% decline in Regeneron’s stock price, which ...